News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,720 Results
Type
Article (41742)
Company Profile (292)
Press Release (690668)
Multimedia
Podcasts (99)
Webinars (20)
Section
Business (205773)
Career Advice (2044)
Deals (35704)
Drug Delivery (130)
Drug Development (81718)
Employer Resources (173)
FDA (16534)
Job Trends (15036)
News (348109)
Policy (32866)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2612)
Accelerated approval (45)
Adcomms (26)
Allergies (169)
Alliances (49929)
ALS (207)
Alzheimer's disease (1784)
Antibody-drug conjugate (ADC) (441)
Approvals (16899)
Artificial intelligence (648)
Autoimmune disease (270)
Automation (54)
Bankruptcy (365)
Best Places to Work (11658)
BIOSECURE Act (21)
Biosimilars (220)
Biotechnology (190)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (741)
Cancer (5738)
Cardiovascular disease (459)
Career advice (1735)
Career pathing (41)
CAR-T (322)
CDC (57)
Celiac Disease (3)
Cell therapy (870)
Cervical cancer (46)
Clinical research (70823)
Collaboration (2048)
Company closure (5)
Compensation (1368)
Complete response letters (77)
COVID-19 (2754)
CRISPR (107)
C-suite (1103)
Cystic fibrosis (152)
Data (7662)
Decentralized trials (3)
Denatured (32)
Depression (160)
Dermatology (80)
Diabetes (581)
Diagnostics (6932)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (316)
Drug pricing (203)
Drug shortages (31)
Duchenne muscular dystrophy (281)
Earnings (91847)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119757)
Executive appointments (1079)
FDA (20189)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1713)
Gene editing (233)
Generative AI (54)
Gene therapy (703)
GLP-1 (1052)
Government (4741)
Grass and pollen (6)
Guidances (405)
Healthcare (19000)
HIV (77)
Huntington's disease (57)
IgA nephropathy (96)
Immunology and inflammation (292)
Immuno-oncology (90)
Indications (180)
Infectious disease (3095)
Inflammatory bowel disease (219)
Inflation Reduction Act (16)
Influenza (137)
Intellectual property (287)
Interviews (319)
IPO (16695)
IRA (52)
Job creations (3681)
Job search strategy (1442)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (571)
Leadership (38)
Legal (7989)
Liver cancer (99)
Longevity (33)
Lung cancer (755)
Lymphoma (424)
Machine learning (59)
Management (59)
Manufacturing (1019)
MASH (183)
Medical device (13923)
Medtech (14031)
Mergers & acquisitions (20235)
Metabolic disorders (1483)
mRNA (199)
Multiple sclerosis (186)
NASH (17)
Neurodegenerative disease (408)
Neuropsychiatric disorders (105)
Neuroscience (3275)
Neurotech (1)
NextGen: Class of 2026 (6558)
Non-profit (4541)
Now hiring (77)
Obesity (696)
Opinion (289)
Ovarian cancer (215)
Pain (249)
Pancreatic cancer (296)
Parkinson's disease (354)
Partnered (35)
Patents (587)
Patient recruitment (662)
Peanut (61)
People (59868)
Pharmaceutical (61)
Pharmacy benefit managers (32)
Phase 1 (22093)
Phase 2 (31205)
Phase 3 (23210)
Pipeline (8202)
Policy (313)
Postmarket research (2569)
Preclinical (9415)
Press Release (65)
Prostate cancer (292)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1059)
Real estate (6015)
Recruiting (70)
Regulatory (25390)
Reports (56)
Research institute (2420)
Resumes & cover letters (354)
Rett syndrome (36)
RNA editing (23)
RSV (88)
Schizophrenia (176)
Series A (293)
Series B (212)
Service/supplier (13)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3692)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (88)
The Weekly (65)
Vaccines (1090)
Venture capital (108)
Weight loss (448)
Women's health (122)
Worklife (20)
Date
Today (202)
Last 7 days (873)
Last 30 days (3186)
Last 365 days (30404)
2026 (11407)
2025 (30327)
2024 (35323)
2023 (40175)
2022 (51291)
2021 (55834)
2020 (54170)
2019 (46641)
2018 (35121)
2017 (32223)
2016 (31629)
2015 (37708)
2014 (31456)
2013 (26503)
2012 (28770)
2011 (29430)
2010 (27528)
Location
Africa (744)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (39844)
Australia (6549)
California (13038)
Canada (3701)
China (1312)
Colorado (559)
Connecticut (563)
Delaware (396)
Europe (86276)
Florida (1948)
Georgia (417)
Hawaii (3)
Idaho (63)
Illinois (1037)
India (89)
Indiana (595)
Iowa (23)
Japan (519)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1564)
Massachusetts (9296)
Michigan (357)
Minnesota (707)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (85)
New Jersey (3432)
New Mexico (28)
New York (3403)
North Carolina (1649)
North Dakota (8)
Northern California (6512)
Ohio (390)
Oklahoma (23)
Oregon (43)
Pennsylvania (2621)
Puerto Rico (29)
Rhode Island (50)
South America (1115)
South Carolina (85)
South Dakota (2)
Southern California (5138)
Tennessee (210)
Texas (2067)
United States (46003)
Utah (387)
Vermont (1)
Virginia (311)
Washington D.C. (81)
Washington State (1050)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
732,720 Results for "igm biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.
January 10, 2025
·
1 min read
·
Angela Gabriel
Layoffs
Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM
After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review of potential strategic alternatives and options for the business.
May 9, 2025
·
2 min read
·
Tristan Manalac
Business
IGM Biosciences Announces Refocusing of Sanofi Collaboration
IGM Biosciences, Inc. today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.
April 17, 2024
·
4 min read
Press Releases
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
·
17 min read
Biotech Bay
IGM Biosciences to Present at the 2024 Jefferies Healthcare Conference
IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.
May 29, 2024
·
1 min read
Press Releases
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
July 2, 2025
·
6 min read
Biotech Bay
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
IGM Biosciences, Inc. announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT.
May 7, 2024
·
1 min read
Business
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.
May 8, 2024
·
9 min read
Press Releases
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 21, 2026
·
5 min read
Biotech Bay
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT.
April 10, 2024
·
1 min read
1 of 73,272
Next
